Acquisition by Fisher Mary of 8602 shares of Dermata Therapeutics subject to Rule 16b-3

DRMA Stock  USD 7.06  0.61  9.46%   
About 55% of Dermata Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Dermata Therapeutics stock suggests that some investors are interested at this time. The current market sentiment, together with Dermata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Dermata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Filed transaction by Dermata Therapeutics Director . Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Dermata insider trading alert for acquisition of common stock by Fisher Mary, Director: , on 26th of February 2025. This event was filed by Dermata Therapeutics with SEC on 2022-07-07. Statement of changes in beneficial ownership - SEC Form 4

Dermata Therapeutics Fundamental Analysis

We analyze Dermata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Dermata Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Dermata Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermata Therapeutics stock to make a market-neutral strategy. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with similar companies.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories